Increased patient and occupational safety for home infusion of cytotoxic and other hazardous drugs


Tada Medical collaborates with Gasgon Medical

We are delighted to announce our collaboration with Gasgon Medical for the development of a novel device for reducing risks for air embolism and IV-line dislodgement. This can strongly increase the safety for patients and nurses during IV therapy at home. There is an increasing demand for intravenous (IV) oncology therapy in a homecare setting. From a healthcare system point of view, up to 90% of the costs could be cut comparing IV therapy given at home to the same care conducted in a hospital setting. From the patient perspective, several studies have shown that the overall experience of treatment is much improved in a homecare setting without a lesser clinical outcome.


How Tada Medical AB and Gasgon Medical reduce drug exposure and flow rate disruption


A proof-of-concept device to address these specific risks has been developed. The disposable closed system device consists of an automatic vent to remove air combined with ReLink that disconnects when the IV line is forcefully pulled. The vent eliminates the need for manual removal of air bubbles, thus reducing drug exposure and disruption to flow rates. ReLink has valves that seal the system on both sides to retain all liquids in the event of a pulled IV line, reducing injury from dislodgement and drug exposure. Feasibility testing of the device has shown a 99.97% success at air removal compared to standard IV delivery methods and reduction in dislodgment frequency of 92%. An abstract based on the initial studies has also been published in the Annals of Oncology.


Disclosure

R.S. Bejhed: Leadership role, Shareholder/Stockholder/Stock options, Full/Part-time employment, Officer/Board of Directors: Tada Medical AB. V.P. Forde: Leadership role, Shareholder/Stockholder/Stock options, Full/Part-time employment, Officer/Board of Directors: Gasgon Medical.


Article Info

DOI: https://doi.org/10.1016/j.annonc.2020.08.2129

177 views

Related Posts

See All